Abstract: TH-PO1033
Incidence of Biopsy-Proven Kidney Disease Among Kaiser Permanente Northern California Patients in 2018
Session Information
- Glomerular Diseases: Epidemiology, Mechanisms, Complications, Outcomes
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Charu, Vivek, Stanford University School of Medicine, Palo Alto, California, United States
- Aghighi, Maryam, Stanford University School of Medicine, Palo Alto, California, United States
- Lapasia, Jessica B., The Permanente Medical Group, Northern California, California, United States
- Lai, George, The Permanente Medical Group, Northern California, California, United States
- Lin, Jennifer W., The Permanente Medical Group, Northern California, California, United States
- Jonelis, Tracy Y., The Permanente Medical Group, Northern California, California, United States
- Troxell, Megan L., Stanford University School of Medicine, Palo Alto, California, United States
- Kambham, Neeraja, Stanford University School of Medicine, Palo Alto, California, United States
- Zheng, Sijie, The Permanente Medical Group, Northern California, California, United States
Background
Accurate population-level estimates of the incidence of glomerular (G) and primary tubulointerstitial diseases (TI) are lacking. Obtaining such estimates is challenging as accurate diagnosis typically requires a kidney biopsy and lack relevant population-level denominators. Here we provide population-level estimates of biopsy-proven G & TI diseases in a cohort of ~4.3 million at Kaiser Permanente Northern California (KPNC) in 2018.
Methods
We reviewed all KPNC 2018 renal biopsy reports, and categorized patients into known G & TI disease groups. Incidence rates and associated standard deviations were calculated per 100,000 persons, stratified by age and sex.
Results
673 native kidney biopsies were performed in 2018, corresponding to 15.8 biopsies/100,000 persons. The incidence of common biopsy-confirmed G & TI diseases are provided in the Table. IgA nephropathy is the most common diagnosis (incidence 2.3/100,000 persons), followed by focal and segmental glomerulosclerosis (1.6/100,000), lupus nephritis (1.4/100,000), pauci-immune GN (1.3/100,000), and membranous nephropathy (1.3/100,000). 19.5% patients undergoing kidney biopsy in this cohort had evidence of diabetic nephropathy (n=131), 21.4% of whom had an additional G or TI diagnosis (n=28).
Conclusion
Here we provide incidence estimates of biopsy-confirmed G & TI diseases in a large, racially and ethnically diverse population. Comparison with population-level estimates in other cohorts will help determine the true incidence of these diseases.
Biopsy-proven kidney disease, KPNC, 2018. *Incidence rates/100,000 persons
| Total (rate*; SE) | Males (rate*; SE) | Females (rate*; SE) | |
| All biopsies | 673 (15.8; 0.6) | 339 (15.4; 0.8) | 334 (16.3; 0.9) |
| IgA nephropathy | 96 (2.3; 0.2) | 50 (2.3; 0.3) | 46 (2.2; 0.3) |
| Focal and segmental glomerulosclerosis | 70 (1.6; 0.2) | 45 (2.0; 0.3) | 25 (1.2; 0.2) |
| Lupus nephritis | 58 (1.4; 0.2) | 7 (0.3; 0.1) | 51 (2.5; 0.3) |
| Pauci-immune glomerulonephritis | 55 (1.3; 0.2) | 20 (0.9; 0.2) | 35 (1.7; 0.3) |
| Membranous nephropathy | 55 (1.3; 0.2) | 33 (1.5; 0.3) | 22 (1.1; 0.2) |
| Light chain cast nephropathy and monoclonal gammopathies of renal significance | 22 (0.5; 0.1) | 11 (0.5; 0.2) | 11 (0.5; 0.2) |
| Acute tubular injury | 21 (0.5; 0.1) | 11 (0.5; 0.2) | 10 (0.5; 0.2) |
| Minimal change disease | 19 (0.5; 0.1) | 10 (0.5; 0.1) | 9 (0.4; 0.2) |
| Thrombotic microangiopathy | 19 (0.5; 0.1) | 9 (0.4; 0.1) | 10 (0.5; 0.2) |
| Acute interstitial nephritis | 17 (0.4; 0.1) | 7 (0.3; 0.1) | 10 (0.5; 0.2) |
| Infection-associated glomerulonephritis | 15 (0.2; 0.1) | 12 (0.5; 0.2) | 3 (0.2; 0.1) |
| Amyloidosis | 14 (0.3; 0.1) | 5 (0.2; 0.1) | 9 (0.4; 0.2) |